ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Russell Investments Core Plus Bond ETF
24.24
0.0000
成交量:
6
成交額:
145.22
市值:
5,684.47萬
市盈率:
- -
高:
24.24
開:
24.24
低:
24.24
收:
24.24
52周最高:
25.19
52周最低:
24.24
股本:
234.50萬
流通股本:
234.50萬
量比:
0.10
換手率:
0.00%
股息:
0.23
股息率:
0.93%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
480家藥企,最新營收、淨利潤來了
赛柏蓝
·
09/08
港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條
智通财经
·
08/27
【券商聚焦】國投證券維持康諾亞-B(02162)買入評級 指核心產品放量及BD兑現
金吾财讯
·
08/26
信達生物:對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入
智通财经
·
08/26
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BD"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":24.2408,"timestamp":1789482767432,"preClose":24.2408,"halted":0,"volume":6,"delay":0,"changeRate":0,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-15 14:39:15 EDT","open":24.2408,"high":24.2408,"low":24.2408,"amount":145.2192,"amplitude":0,"askPrice":24.28,"askSize":100,"bidPrice":24.14,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":24.2408,"nav":24.335265,"aum":57066195.36,"dividendRate":0.009311,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.249,"preClose":24.2408,"latestTime":"16:04 EDT","volume":2,"amount":48.4816,"timestamp":1789416246882,"change":0.0082,"changeRate":0.000338,"amplitude":0},"volumeRatio":0.096527},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BD\",,,,,undefined,":{"symbol":"BD","floatShares":2345000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.096527,"shares":2345000,"dividePrice":0.2257,"high":24.2408,"amplitude":0,"preClose":24.2408,"low":24.2408,"week52Low":24.2408,"pbRate":"--","week52High":25.19,"institutionHeld":0,"latestPrice":24.2408,"eps":0,"divideRate":0.009311,"volume":6,"delay":0,"ttmEps":0,"open":24.2408,"prevYearClose":25.08,"prevWeekClose":24.249,"prevMonthClose":24.7551,"prevQuarterClose":25.19,"fiveDayClose":24.615,"twentyDayClose":24.725},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BD\",params:#limit:5,,,undefined,":[{"date":"2026-09-02","symbol":"BD","amount":0.104028,"announcedDate":"2026-09-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-02","defaultRemindTime":1788355800000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-04","payableDate":"2026-09-02","currency":"USD","dateTimestamp":1788321600000,"payDate":"2026-09-04"},{"date":"2026-08-04","symbol":"BD","amount":0.120736,"announcedDate":"2026-08-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-04","defaultRemindTime":1785850200000,"name":"Russell Investments Core Plus Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-06","payableDate":"2026-08-04","currency":"USD","dateTimestamp":1785816000000,"payDate":"2026-08-06"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BD\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-04","recordDate":"2026-08-04","paymentDate":"2026-08-06","value":0.120736,"currency":"USD"},{"executeDate":"2026-09-02","recordDate":"2026-09-02","paymentDate":"2026-09-04","value":0.104028,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BD\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665320971","title":"480家藥企,最新營收、淨利潤來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320971","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:39","pubTimestamp":1788867540,"startTime":"0","endTime":"0","summary":"2026年上半年,480家药企合计实现营收7,369.82亿元,同比增长+2.48%;实现归母净利润988.94亿元,同比增长+12.35%。荣昌生物营收58.53亿元,归母净利润46.62亿元,主要受海外授权合作首付款及里程碑款驱动,是板块利润暴增的最大来源。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircmeq9268445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股異動 | 樂普生物(02157)午後升逾5% 上半年收入按年增長12.1% 即將跑通CMG901的BD全鏈條","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773564?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上,近日,乐普生物发布截至2026年6月30日止六个月业绩,收入5.22亿元,同比增长12.1%;公司拥有人应占利润2739.3万元,同比下降34.4%;每股基本盈利0.02元。国联民生证券发布研报称,乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent,实现研发能力变现。在商业模式上,公司已成功构建并验证了国内商业化能力,同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动,持续优化收入结构。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","02157","VXUS","BK1161","KCAI","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】國投證券維持康諾亞-B(02162)買入評級 指核心產品放量及BD兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662623760?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指,康诺亚-B 2026年中期实现营业收入6.17亿元人民币,同比增长24%;实现净利润12.18亿元人民币,上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日,公司现金及金融资产合计32.42亿元人民币,较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展,维持“买入-A”评级,根据DCF模型给予6个月目标价90.37港元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","KCE","BD","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662994764","title":"信達生物:對2030年總收入預期較為保守 BD首付款將有效覆蓋研發投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2662994764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662994764?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 11:58","pubTimestamp":1787716704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BD\",params:#limit:6,delay:false,,,undefined,":[]}}